

Surgery Interest Group

#3.316

Epilepsy Surgery in Tuberous Sclerosis Complex

Results from The Pediatric Epilepsy Research Consortium (PERC) Epilepsy Surgery Database
Eschbach K¹, Karia S², Depositario-Cabacar D³, Singh RK⁴, Ostendorf AP⁵, McNamara NA⁶, Romanowski E⁶, Sullivan J⁷, Nangia S⁸, Grinspan Z⁸, Bolton J⁹, Reddy SB¹⁰, Manuel C¹⁰, Shrey DW11, Tatachar P12, Marashly A13, Ciliberto MA14, Gedela S15, Koop J16, Coryell J17, Wolf S18, McGoldrick P18, Wong-Kisiel L19, Shandley S20, Perry MS20, Alexander AL1

1Children's Hospital Colorado, University of Colorado Anschutz Medical Campus. 2Norton Children's Hospital, University of Louisville School of Medicine, 3Children's National Hospital, George Washington University School of Medicine, 4Atrium Health/Levine Children's Hospital, 5Nationwide Children's Hospital, Ohio State University, 6Michigan Medicine, University of Michigan, 7University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, 8Weill-Cornell Medicine, 9Boston Children's Hospital, 10Vanderbilt University Medical Center, Monroe Carell Jr Children's Hospital

RATIONALE

- Tuberous Sclerosis Complex (TSC) is a leading cause of genetic structural epilepsy in childhood and is often drug-resistant.
- Variations in care are understudied, including presurgical evaluation, recommended surgical treatments, the use of palliative resections, and surgical outcomes.

METHODS

- Children 0-18 years of age with TSC were included from the PERC Epilepsy Surgery Database, a prospective cross sectional study enrolling patients undergoing epilepsy surgery evaluation at 20 US pediatric epilepsy centers.
- Predefined variables collected included demographics, epilepsy characteristics, presurgical treatment, epilepsy evaluation, goal of surgery (palliative vs definitive), and outcome of surgery.
- Data was obtained from database initiation in 1/2018 to present 5/2021.


Children in database: 1037


Children with TSC: 36

Patient and Epilepsy Characteristics

Age at seizure onset (median)	0.3 years (IQR 0.3-0.65)
Age at failure of second ASM (median)	1.5 years (IQR 0.9 – 4)
Age at referral for current phase I (median)	4.1 years (IQR 2.0 – 9.1)
# of failed ASM prior to phase I (median)	4 (IQR 2-5)
# with history of prior epilepsy surgery	9 children

ASM: antiseizure medication Type of Surgery Performed (n=16)





- No additional testing after phase I evaluation in 15 (42%)
- Additional testing (MEG, PET, and / or SPECT) completed in 21 (58%)
 - MEG (11), PET (11), SPECT (7); 2 modalities (4), 3 modalities (2)
- Surgery offered in 25 (69%)


Lesionectomy

- 1-stage surgery in 11 (31%)
- 2-stage surgery in 15 (42%) with stereo-EEG completed in 10
- One child offered either a 1-stage or 2-stage surgery
- Intent of surgery palliative in 10 (63% who underwent surgery)
- Reason surgery not offered: inadequate data (4), multifocal onset (3), risk of injury outweighed benefit (2), > one of these (3), not reported (4)

RESULTS

Median duration of follow-up is 7.5 months (IQR 1-10.4).

Ten children have at least 6 months of follow-up since epilepsy surgery (range 6-27 months).



CONCLUSIONS

- Children with TSC referred for consideration of epilepsy surgery have an early onset of epilepsy and early drug-resistance.
- The extent of pre-surgical evaluation and additional testing after phase I evaluation is variable.
- Surgery is often intended to be palliative and most often consists of focal resections.
- Ongoing follow-up of this cohort will provide insight into potential benefits of palliative epilepsy surgery in children with TSC.



